Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients: A Seer-Medicare-Based Modelling Analysis
A Seer-Medicare-Based Modelling Analysis [MEETING ABSTRACT PCN91]
Parikh, R., Du, XL., Morgan, RO., & Lairson, DR. (2016). Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients: A Seer-Medicare-Based Modelling Analysis: A Seer-Medicare-Based Modelling Analysis [MEETING ABSTRACT PCN91]. Value in Health, 19(3), A150. https://doi.org/10.1016/j.jval.2016.03.1590
Abstract
Treatment sequences with bevacizumab at first-line and targeted biologics at third-line may not be cost-effective at the commonly used threshold of $100,000/QALY gained but a marginal decrease in the cost of bevacizumab may make treatment sequences with first-line bevacizumab cost-effective. Future economic evaluations should validate the study results using parameters from ongoing clinical trials.
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.